Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.

@article{Dowlati2007PhaseIT,
  title={Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.},
  author={Afshin Dowlati and Shanmuga P. Subbiah and Matthew A Cooney and Kimberly Rutherford and Tarek Abdel-Malak Mekhail and Pingfu Fu and Robert A. Chapman and Anne B Ness and Tania Cortas and Joel A Saltzman and Nathan I. Levitan and Gregory L. Warren},
  journal={Lung cancer},
  year={2007},
  volume={56 3},
  pages={
          377-81
        }
}
BACKGROUND Extensive-stage small cell lung cancer (SCLC) is a highly aggressive malignancy for which little therapeutic progress has been made over the past 20 years. SCLC is a highly angiogenic tumor and targeting angiogenesis is being investigated. The putative mechanism of action of thalidomide is through inhibition of new blood vessel formation. This trial was designed to evaluate thalidomide in ES-SCLC. PATIENTS AND METHODS Patients who had received first-line chemotherapy without… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Similar Papers

Loading similar papers…